BlackRock, Inc. 13D and 13G filings for BioXcel Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-09 09:02 am Sale | 2023-01-31 | 13G | BioXcel Therapeutics, Inc. BTAI | BlackRock Inc. BLK | 1,312,403 4.700% | -150,519 (-10.29%) | Filing |
| 2023-02-03 12:10 pm Purchase | 2022-12-31 | 13G | BioXcel Therapeutics, Inc. BTAI | BlackRock Inc. BLK | 1,462,922 5.200% | 1,462,922 (New Position) | Filing |